JNJ 87801493
Alternative Names: JNJ-87801493Latest Information Update: 27 Dec 2023
At a glance
- Originator Janssen Research & Development
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma
Most Recent Events
- 06 Dec 2023 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater, Combination therapy) in Australia (SC) (NCT06139406)
- 18 Nov 2023 Janssen Research & Development plans a phase I trial for Non-Hodgkin lymphoma (Combination therapy, Second-line therapy or greater) (SC) in December 2023 (NCT06139406)
- 18 Nov 2023 Preclinical trials in Non-Hodgkin's lymphoma in USA (SC) (NCT06139406)